Difference between revisions of "Daunorubicin (Cerubidine)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - " " to " ") |
Warner-admin (talk | contribs) m (Text replacement - "please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [https://online.lexi.com/lco/action/login UpToDate Lexidrug], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information" to "please refer to your preferred pharmacopeias or the prescribing information") |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: [[vesicant]] | <br>Extravasation: [[vesicant]] | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 16: | Line 16: | ||
</ref>, daunorubicin appears to be significantly less cardiotoxic than doxorubicin in survivors of childhood cancer. | </ref>, daunorubicin appears to be significantly less cardiotoxic than doxorubicin in survivors of childhood cancer. | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[https://chemocare.com/ | + | *[https://chemocare.com/druginfo/daunorubicin.aspx Daunorubicin (Cerubidine) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/daunorubicin.aspx Daunorubicin (Cerubidine) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/daunorubicin-patient-drug-information Daunorubicin (Cerubidine) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/daunorubicin-patient-drug-information Daunorubicin (Cerubidine) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/daunorubicin-patient-drug-information Daunorubicin (Cerubidine) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/daunorubicin-patient-drug-information Daunorubicin (Cerubidine) patient drug information (UpToDate)]</ref> | ||
| Line 23: | Line 23: | ||
*Uncertain date: Approved in combination with other approved anticancer drugs for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults. ''(Based on Yates et al. 1973, possibly others)'' | *Uncertain date: Approved in combination with other approved anticancer drugs for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults. ''(Based on Yates et al. 1973, possibly others)'' | ||
*Uncertain date: Approved for remission induction in [[:Category:Acute lymphoblastic leukemias|acute lymphocytic leukemia]] of children and adults. ''(Based on ALGB 6801 & CALGB 7612)'' | *Uncertain date: Approved for remission induction in [[:Category:Acute lymphoblastic leukemias|acute lymphocytic leukemia]] of children and adults. ''(Based on ALGB 6801 & CALGB 7612)'' | ||
| − | + | ==History of changes in EMA indication== | |
| + | *1966-06-08: EURD | ||
==Patient Information== | ==Patient Information== | ||
*[http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Ben+Venue_Bedford+Labs/55390-108-01+DNOP_AQ+20mg/5539010801 Daunorubicin (Cerubidine) package insert]<ref name="insert"></ref> | *[http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Ben+Venue_Bedford+Labs/55390-108-01+DNOP_AQ+20mg/5539010801 Daunorubicin (Cerubidine) package insert]<ref name="insert"></ref> | ||
| Line 38: | Line 39: | ||
[[Category:Anthracyclines]] | [[Category:Anthracyclines]] | ||
| − | [[Category:Topoisomerase inhibitors]] | + | [[Category:Topoisomerase II inhibitors]] |
[[Category:B-cell acute lymphoblastic leukemia medications]] | [[Category:B-cell acute lymphoblastic leukemia medications]] | ||
| Line 46: | Line 47: | ||
[[Category:FDA approved in 1979]] | [[Category:FDA approved in 1979]] | ||
| + | [[Category:EMA approved in 1966]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Latest revision as of 00:57, 29 June 2024
General information
Class/mechanism: Anthracycline, binds and intercalates between DNA base pairs. Inhibits topoisomerase II activity by stabilizing the DNA-topoisomerase II complex, resulting in single and double strand DNA breaks. May also inhibit polymerase activity and trigger free radical damage to DNA.[1][2]
Route: IV
Extravasation: vesicant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.[1]
Diseases for which it is used
- B-cell acute lymphoblastic leukemia
- Acute myeloid leukemia
- Acute promyelocytic leukemia
- T-cell acute lymphoblastic leukemia
Toxicity information
- Per Feijen et al. 2015 [3], daunorubicin appears to be significantly less cardiotoxic than doxorubicin in survivors of childhood cancer.
Patient drug information
- Daunorubicin (Cerubidine) patient drug information (Chemocare)[4]
- Daunorubicin (Cerubidine) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 1979-12-19: Initial FDA approval
- Uncertain date: Approved in combination with other approved anticancer drugs for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults. (Based on Yates et al. 1973, possibly others)
- Uncertain date: Approved for remission induction in acute lymphocytic leukemia of children and adults. (Based on ALGB 6801 & CALGB 7612)
History of changes in EMA indication
- 1966-06-08: EURD
Patient Information
Also known as
- Generic name: daunomycin
- Brand names: Cerubidin, Cerubidine, D-Blastin, Daunoblastin, Daunoblastina, Daunocin, Daunomicina, Daunorubicine, Daurocina, Maxidauno, Ondena, Rubidomycin, Rubilem, Rubomycin, Runabicon
References
- ↑ 1.0 1.1 1.2 Daunorubicin (Cerubidine) package insert
- ↑ Daunorubicin (Cerubidine) package insert (locally hosted backup)
- ↑ Feijen EA, Leisenring WM, Stratton KL, Ness KK, van der Pal HJ, Caron HN, Armstrong GT, Green DM, Hudson MM, Oeffinger KC, Robison LL, Stovall M, Kremer LC, Chow EJ. Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. J Clin Oncol. 2015 Nov 10;33(32):3774-80. Epub 2015 Aug 24. link to original article link to PMC article PubMed
- ↑ Daunorubicin (Cerubidine) patient drug information (Chemocare)
- ↑ Daunorubicin (Cerubidine) patient drug information (UpToDate)
Categories:
- Drugs
- Intravenous medications
- Vesicant
- Anthracyclines
- Topoisomerase II inhibitors
- B-cell acute lymphoblastic leukemia medications
- Acute myeloid leukemia medications
- Acute promyelocytic leukemia medications
- T-cell acute lymphoblastic leukemia medications
- FDA approved in 1979
- EMA approved in 1966
- WHO Essential Cancer Medicine